Skip to main content
SpringerLink
Log in

Das Prostatakarzinom: Wissenschaftliche Grundlagen und Behandlung

  • Conference paper
Fortschritte in Diagnostik und Therapie des Prostatakarzinoms

  • 15 Accesses

Zusammenfassung

Das Prostatakarzinom ist der zweithäufigste Krebs des Mannes. Seine Inzidenz hat sich im Laufe der letzten 30 Jahre praktisch verdoppelt. Die molekularen Ursprünge des Prostatakarzinoms sind nicht bekannt. Die Expression des P 21- Proteins, Produkt des ras-Onkogens, erlaubt eine Unterscheidung zwischen einem Prostatakarzinom und einer gutartigen Prostatahyperplasie. Bei 23 von 29 Prostatakarzinomen wurde das P 21-Protein exprimiert, jedoch bei keinem von 19 untersuchten Patienten mit benigner Prostatahyperplasie. Dieses korrelierte ebenfalls positiv mit dem Differenzierungsgrad der Tumoren (Viola et al. 1986). Bei nur einem von 24 Prostatakarzinomen wurden Mutationen des ras-Onkongens beschrieben (Carter et al. 1990).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Beland G, Elhilali M, Fradet Y et al. (1990) Randomized study comparing orchiectomy and anandron in advanced prostate cancer. Gynecol Endrocrinol 4 [Suppl 2]: 81

    Google Scholar 

  • Bertagna C (1990) Treatment of metastatic prostate cancer with orchiectomy and anandron (Nilutamide): results of a double-blind study versus orchiectomy and placebo. Gynecol Endocrinol 4 [Suppl 2]: 82

    Google Scholar 

  • Blackard CE, Byar DP, Jordan WP, Vacurg (1973) Orchiectomy for advanced prostatic carcinoma. Urology 1 (6): 553

    CAS  Google Scholar 

  • Boccardo F (1990) Treatment of prostatic cancer with LH-RH analogues alone or in combination with pure antiandrogens. Gynecol Endocrinol 4 [Suppl 2]: 84

    Google Scholar 

  • Bookstein R, Shew JY, Chen PL, Scully P, Lee WH (1990) Suppression of tumorigenicity of human prostate carcinoma cells by reoplacing a mutated RB gene. Science 247: 712

    Article  PubMed  CAS  Google Scholar 

  • Carter BS, Epstein JI, Isaacs WB (1990) ras Gene mutations in human prostate cancer. Cancer Res 50: 6830

    Google Scholar 

  • Crawford ED, Eisenberger MA, McLeod DG et al. (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321 (7): 419

    Article  PubMed  CAS  Google Scholar 

  • Crawford ED, Bertagna C, Smith JA et al. (1990) A randomized, controlled clinical trial of leuprolide and anandron versus leuprolide and placebo for advanced prostate cancer. Gynecol Endocrinol 4 [Suppl 2]: 85

    Article  Google Scholar 

  • De Voogt HJ, Klijn JG, Studer U, Schroeder FG, Sylverster R, de Pauw M, members of the EORTC- GU Group (1990) Comparison of orchidectomy and buserelin combined with anti androgens in the treatment of advanced prostatic cancer. (EORTC-trial 30843). Gynecol Endocrinol 4 [Suppl 2]: 83

    Google Scholar 

  • Ferrari P, Castagnetti G, Pollastri C, Ferrari G, Tavoni F, Grassi D (1990) LHRH analogue buserelin versus buserelin and flutamide in the treatment of advanced metastatic prostatic carcinoma. Five Years Experience. Gynecol Endocrinol 4 [Suppl 2]: 87

    Google Scholar 

  • Fleming WH, Hamel A, MacDonald R et al. (1986) Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res 46: 1535

    PubMed  CAS  Google Scholar 

  • Fourcade O, Carion G, Coloby P, Grise P, Mang P, Soret J, Poteri M (1990) Total androgen blockade in advanced prostate carcinoma: interim report of a double blind study using, zoladex and flutamide. Gynecol Endocrinol 4 [suppl 2]: 89

    Google Scholar 

  • Fowler JE Jr, Lau JLT, Ghosh L, Mills SE, Mounzer A (1988) Epidermal growth factor and prostatic carcinoma: an immunohistochemical study. J Urol 139: 857

    PubMed  Google Scholar 

  • Haefliger JM (1990) A multicentre randomised trial comparing the LHRH analogue’zoladex’ vs’zoldaex’ in combination with flutamide in the treatment of advanced prostate cancer. Gynecological Endocrinology 4 [Suppl 2]: 88

    Google Scholar 

  • Huggins C, Hodges CV (1941) The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 292

    Google Scholar 

  • Iversen P Danish Prostatic Cancer Group (1990) Daproca 86-zoladex and flutamide versus orchiectomy for advanced prostatic cancer. Gynecol Endocrinol 4 [Suppl 2[: 88

    Google Scholar 

  • Lunglmayr G (1989) Casodex (ICI 176,334), a new, non-steroidal anti-androgen. Early clinical results. Horm Res 32 [Suppl 1]: 77

    Article  PubMed  Google Scholar 

  • MacDonald A, Chisholm GD, Habib FK (1990) Production and response of a human prostatic cancer line to transforming growth factor-like molecules. Br J Cancer 62: 579

    Article  PubMed  CAS  Google Scholar 

  • Mahler C, Pinto de Carvalho A, Smith Ph, members of the EORTC GU Group (1990) Randomized study of orchiectomy versus zoladex and flutamide in metastatic prostatic cancer. Gynecol Endocrinol 4 [Suppl 2]: 81

    Google Scholar 

  • Morris GL, Green Dodd J (1990) Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines. J Urol 143: 1272

    PubMed  CAS  Google Scholar 

  • Neri R, Kassem N (1984) Biological and clinical properties of antiandrogens. In: Bresciani F, King RJB, Lippman ME, Namer M, Raynaud JP (eds) Hormones and cancer 2: proceedings of the 2nd international congress on hormones and cancer. Raven, New York, p 507 (Progress in cancer research and therapy, vol 31 )

    Google Scholar 

  • Nesbit RM, Baum WC (1950) Endocrine control of prostatic carcinoma: clinical and statistical survey of 1,818 cases. JAMA 143: 1317

    Article  CAS  Google Scholar 

  • Osborne CK, Blumenstein B, Crawford ED et al. (1990) Combined versus sequential chemo-en- docrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group Study. J Clin Oncol 8: 1675

    PubMed  CAS  Google Scholar 

  • Pavone-Macaluso M, de Voogt HJ, Viggiano G et al. (1986) Comparison of diethystilbestrol, cyproterone acetate and medrocyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization For Research On Treatment Of Cancer Urological Group. J Urol 136: 624

    PubMed  CAS  Google Scholar 

  • Qayum A, Gullick W, Clayton RC, Sikora K, Waxman J (1990) The effects of gonadotrophs releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer 62: 96

    Article  PubMed  CAS  Google Scholar 

  • Rijinders AWM, van der Korput JAGM, van Steenbrugge GJ, Romijn JC, Trapman J (1985) Expression of cellular oncogenes in human prostatic carcinoma cell lines. Biochem Biophys Res Commun 132 (2): 548

    Article  Google Scholar 

  • Sogani OC, Ray B, Whitmore WF Jr (1975) Advanced prostatic carcinoma. Urology VI: 164

    Google Scholar 

  • Trachtenberg T, Walsh PC (1982) Correlation of prostatic nuclear androgen receptor content with duration of respinse and survival following hormonal therapy in advanced prostatic cancer. J Urol 127: 466

    PubMed  CAS  Google Scholar 

  • Treiger B, Isaacs J (1988) Expression of a transfected v-Harvey-ras oncogene in a Dunning rat prostate adenocarcinoma and the development of high metastatic ability. J Urol 140: 1580

    PubMed  CAS  Google Scholar 

  • Veterans Administration Cooperative Urological Research Group (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124: 1011

    Google Scholar 

  • Viola V, Fromowitz F, Oravez S et al. (1986) Expression of ras oncogene p21 in prostate cancer. N Engl J Med 314: 133

    Article  PubMed  CAS  Google Scholar 

  • Waxman J (1987) Gonadotrophin hormone releasing analogues open new doors in cancer treatment. Br Med J 295: 1084

    Article  CAS  Google Scholar 

  • Waxman J, Williams G, Sandow J et al. (1988) The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue. Am J Clin Oncol II [suppl 2]: 152

    Article  Google Scholar 

  • Waxman J, Sandow J, Abel P, Barton C, Keane P, Wiliams G (1990) Three-monthly GnRH agonist ( Buserelin) for prostatic cancer. Br J Urol 65: 43

    Google Scholar 

  • White JW (1893) The present position of the surgery of the hypertrophied prostate. Ann Surg 18: 152

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. J. Waxman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung für Urologie, Marienkrankenhaus, Alfredstraße 9, 22087, Hamburg, Germany

    Hermann Becker

  2. Akademisches Lehrkrankenhaus, Universität Hamburg, Alfredstraße 9, 22087, Hamburg, Germany

    Hermann Becker

  3. South Gwent Health Unit, St. Woolos Hospital, 131 Stow Hill, NP9 4SZ, Newport, Gwent, Great Britain

    W. B. Peeling

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Waxman, J. (1995). Das Prostatakarzinom: Wissenschaftliche Grundlagen und Behandlung. In: Becker, H., Peeling, W.B. (eds) Fortschritte in Diagnostik und Therapie des Prostatakarzinoms. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79669-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-79669-2_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-59123-8

  • Online ISBN: 978-3-642-79669-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation